Project Venus: Epstein's DNA Collection Program

A database-driven investigation into genetic material collection, cryopreservation, genome sequencing, human germline editing, and the biological infrastructure hidden in the Epstein document archive.

Database: 73,994 email threads + 1,409,216 full-text DOJ/House Oversight documents + kabasshouse curated intelligence (financial records, calendar entries, knowledge graph) Method: Full-text search across all databases, cross-referenced with financial records, calendar entries, curated documents, and the 1.3M-document DOJ corpus Key finding: Epstein systematically collected, stored, and catalogued genetic material — his own cell lines at Harvard, sperm at California Cryobank, DNA test kits distributed to associates worldwide, and enrollment in the Personal Genome Project — while operating a formal USVI "DNA database" business, actively planning offshore human embryo gene editing with a biohacker collaborator, investing $9 million in Illumina stock, and privately musing whether "beauty resides in the DNA"

Part I: "Does the Beauty Reside in the DNA?"link

In June 2006, Jeffrey Epstein wrote to an associate about his plans to fund Harvard's genetic research. His interest wasn't purely scientific:

"I am going to fund the personal genome project at harvard, questions does the beauty reside in the dna, is the formula more elegant, or is it the hunt for complementarity, that determines the eye of the beholder"

— Jeffrey Epstein, June 24, 2006 (ef409f0563684a66)

This question — whether beauty has a genetic basis — captures the intersection of Epstein's scientific curiosity and his documented obsession with controlling reproduction. He wasn't asking as a philosopher. He was asking as someone who would go on to fund the Personal Genome Project, collect his own cell lines, bank his sperm, distribute DNA testing kits across his global network, operate a formal DNA database business in the US Virgin Islands, and plan offshore human embryo gene editing.

Part II: The Personal Genome Project — Epstein Enrollslink

George Church founded the Personal Genome Project (PGP) at Harvard in 2005 as the world's first open-access human genome database. By 2013, Epstein was a participant.

On June 28, 2013, Church arranged for Epstein to undergo a skin cell biopsy and blood draw at Massachusetts General Hospital:

"the MD and biopsy parts are scheduled... need to know the time of day so the technicians can get the skin cells growing"

— George Church, June 2013 (vol00009-efta00388263-pdf)

Dr. Joe Thakuria, Medical Director of the PGP, performed the procedure at MGH's Yawkey building. One month later, Thakuria reported the results to Lesley Groff, Epstein's executive assistant:

"Jeffrey's skin biopsy resulted in several successful, viable fibroblast cultures. Those cell lines are now stored in liquid nitrogen and slated for iPS cell line ('adult stem cells') creation. Essentially, this process requires several culture passages, and reiteration of picking out the right colony for further passages. Success rate of generating iPS cells is relatively high now but the process still takes several months."

— Joe Thakuria to Lesley Groff, August 1, 2013 (EFTA02720568)

Thakuria continued: "On the DNA side of things, I'm working on getting Jeffrey" — the message cuts off in the archive, but the trajectory is clear. Epstein's skin cells were being reprogrammed into induced pluripotent stem cells — cells that can theoretically become any tissue type in the human body.

By September 2013, Groff was following up with both Church and Thakuria about progress on "his genome":

"I have sent Joe Thakuria and cc'd George Church 2 emails asking if they could please give us an update on your genome"

— Lesley Groff, September 21, 2013 (vol00009-efta00383096-pdf)

Church himself was coordinating behind the scenes:

"I've encouraged them to set up a sample status update system."

— George Church, November 2013 (EFTA02121326)

Church later described the PGP biobank in explicitly commercial terms:

"disruptive technologies (precise, fast and inexpensive) for human genome (and microbiome) engineering — especially in the context of our PGP biobank human stem cell samples — which we (& NIST + FDA genomeinabottle.org) feel are the only ones in the world properly consented for broad commercial use"

— George Church, May 5, 2013 (vol00009-efta00677967-pdf)

The PGP biobank was, in Church's own words, the only stem cell collection "properly consented for broad commercial use." Epstein's cells were in it.

The full-text corpus confirms Epstein's PGP enrollment through multiple channels: a Veritas Genetics discount offer addressed to "Dear Jeffrey Epstein" for PGP participants (EFTA01138743), and a PGP newsletter inviting him to "NYC sample collections for a stem cell biobank" (EFTA01193276).

Part III: The Genome Sequencing Paper Traillink

The financial and logistical trail behind Epstein's genome sequencing reveals a persistent, multi-year effort.

December 2013: Thakuria sent Epstein an initial invoice for $324,000 per year for comprehensive genomic services. Epstein rejected it immediately.

February 2014: Thakuria revised the proposal. The whole genome cost through Illumina was $9,500 for standard turnaround or $11,400 for rapid. Thakuria offered an alternative:

"if the budget is only $5,000, I think the most bang for his buck (and this is what I would do for myself with only $5,000 to spend) is to get an exome done"

— Joe Thakuria, February 24, 2014 (EFTA02500395)

Epstein's response was characteristically decisive:

"let's start and do the full genome with rapid turn around. 11,400"

— Jeffrey Epstein via Lesley Groff (EFTA02581206)

Thakuria then asked for an additional $4,000 software budget for secondary analyses beyond Illumina's "black box" interpretation. Epstein:

"give him 10k"

— Jeffrey Epstein (EFTA02500395)

The sequencing required IRB approval at Partners/MGH — Institutional Review Board approval, a formal ethics review. Thakuria confirmed the IRB process in March 2014:

"My study is still awaiting IRB approval at MGH. Once that goes through, there'll be a consent form for Jeffrey to review and sign and then I can forward the invoice from Illumina for the rapid turn-around-time whole genome."

— Joe Thakuria, March 3, 2014 (vol00009-efta00373692-pdf)

In the same email, Thakuria revealed that Epstein was getting the premium treatment: "The YPO folks are also awaiting this MGH IRB approval along with him for work beyond the DNA extraction. They will need to get re-consented... they will have their exomes sequenced while Jeffrey will have his full genome sequenced."

June 2014: Thakuria collected a saliva sample from Epstein during a lunch that also included George Church. He then added Epstein's samples to the YPO exome study — a sequencing batch that included 80+ members of the Young Presidents' Organization from the Austin chapter, each paying $1,000. Epstein was invited to add additional samples:

"Jeffrey can add whoever he want into the YPO exome study but I will need to have those samples mailed to me directly... The exomes (at cost) are $1,000 each."

— Joe Thakuria (EFTA01921074)

Thakuria also sought permission to use Epstein's existing samples: "Jeffrey has samples (including fibroblast cell culture from his skin biopsy) at HMS" for the YPO study (EFTA00368469).

Epstein became the first person to have two separate DNA sources sequenced in parallel. Thakuria confirmed in June 2014: "just to confirm, this would be for Jeffrey's 2 exomes (saliva and fibroblast cell lines), right?" (EFTA01917706). By August 2014, Thakuria noted: "I haven't gotten his fibroblast cell lines into the sequencing queue yet... Jeffrey will be the first to have exomes on 2 cell lines/DNA sources available. So, that analyses will be interesting and unique" (EFTA00365058).

Groff asked Epstein: "do you want to send him the 4 other samples?" — indicating Epstein had additional DNA kits ready to go.

June 2014: Thakuria sent a final invoice:

"The only payment that should go out ASAP is the exome sequencing work. That comes out to $1000 for the saliva sample I collected on Sat from him PLUS $1000 for exome sequencing of his fibroblasts PLUS $1000 for each person he wants to add to the study."

— Joe Thakuria, June 24, 2014 (EFTA02584961)

Epstein paid $2,000. Thakuria's work was "pro bono" beyond the sequencing costs. The check was received and the saliva sample entered the sequencing run.

Total documented payments: $2,000 (exome sequencing) + $1,000 (gift) + $10,000 (genome sequencing budget) = $13,000 for a full genome sequence, fibroblast cultures, iPS cell creation, and liquid nitrogen storage of his biological material.

Part IV: The Sperm Banklink

In May 2016, Epstein sent a direct message to Dr. Harry Fisch — a prominent urologist and male fertility specialist in New York:

"harry i want to bank some sperm, where do I go? prescription?"

— Jeffrey Epstein, May 9, 2016 (vol00009-efta00534034-pdf)

Fisch replied immediately:

"Call 212-779-1608. It's California Cryobank NY. They accept deposits."

Epstein forwarded the information to his staff: "get all the paperwork etc."

Karyna Shuliak — Epstein's girlfriend at the time — coordinated the process. She forwarded the complete California Cryobank semen storage package to Lesley Groff, including the Client Depositor Information form, Determination of Usage form, Consent for Infectious Disease Testing, and Request to Release Laboratory Results (EFTA02702649). Groff then received instructions: "Jeffrey asked for you to fill out all the forms attached below please."

The paperwork moved through multiple hands:

"I have your signed California Cryobank paperwork. Karyna was asking about it yesterday...do you want me to send it to Karyna?"

— Lesley Groff, July 6, 2016 (EFTA02456848)

Shuliak kept pushing the process forward: "Karyna is asking me to please fax your paperwork to Kaitlyn at the California Cryobank again...OK for me to send it?" (EFTA02040348)

Kaitlyn Fraterman, the Client Deposit Coordinator at California Cryobank's New York office (369 Lexington Avenue, 4th Floor), needed to speak with Epstein directly before the appointment:

"Is Jeffrey available to confirm private information? It is imperative that we speak to him prior to his appointment."

— Kaitlyn Fraterman, July 7, 2016 (EFTA02048470)

The full-text corpus reveals the actual signed Specimen Storage Agreement — executed on May 9, 2014, with "JeFFRe'1 C. PSTeIN" at "9 E 71ST STREET, New York" (EFTA00313936). This contract — with its death-of-client provisions binding on "heirs, spouses, executors" (EFTA00313873) — shows Epstein had been storing sperm at California Cryobank since at least 2014, two years earlier than the 2016 Fisch referral chain previously indicated.

A 2012 renewal notice confirms even earlier storage:

"This email serves as a reminder that your storage is due for automatic renewal at the end of this month."

— California Cryobank to Jeffrey Epstein, October 23, 2012 (EFTA01803679)

An associate who forwarded the renewal notice joked:

"Must be a week of deals that fell through... This seems to be from the sperm bank. I thought about just making the payment, or a withdrawal ;) but...here you go. I hope you choose to keep my name on file."

And in June 2018 — just over a year before his arrest — another alert appeared:

"Alert - sperm bank"

— June 5, 2018 (EFTA02644474)

Epstein's iPhone calendar data corroborates the timeline: a "sperm bank" calendar entry on May 9, 2016, and again "sperm" on June 17, 2016 (EFTA01065085).

The timeline spans at least 2012 to 2018 — six years of continuous sperm cryopreservation. Combined with the fibroblast cell lines at Harvard and the iPS cells at MGH, Epstein maintained biological material across at least three facilities.

Part V: 23andMe — DNA Collection Across the Networklink

Epstein didn't just collect his own DNA. He distributed 23andMe genetic testing kits to associates across his global network — and the archive reveals exactly who received them.

The Woody Allen Kit (September 2016)link

"Kits will arrive in 2-3 business days. Merwin please keep an eye out for them...we need to take to Woody Allen once they arrive. Please confirm back"

— September 19, 2016 (EFTA01780903)

Epstein ordered 23andMe kits specifically to collect Woody Allen's DNA.

The Chomsky Kits (April 2017)link

"Jeffrey would like to send 2 genetic kits from 23 and me to Noam and Valeria Chomsky please. Could you please arrange that?"

— Karyna Shuliak, April 15, 2017 (EFTA02210166)

Two kits were drop-shipped from Amazon to linguist Noam Chomsky and his wife Valeria, charged to Karyna Shuliak's credit card and reimbursed through Epstein's accounts.

The Aziza Kit (May 2017)link

"Hello Aziza...I see Amazon says they have delivered your '23 and Me' DNA kit to the address you gave me...says it arrived yesterday...can you confirm receipt?"

— Lesley Groff, May 25, 2017 (EFTA02213951)

The Jabor Y. Kit (February 2017)link

"Jeffrey would like to send you a DNA test... may I please have your address so we may send to you in NY?"

— Lesley Groff to Jabor Y., February 15, 2017 (vol00009-efta00445354-pdf)

Jabor replied: "I am in London now. Please keep it with you." — indicating a Qatari contact in Epstein's DNA distribution network.

The Jabor Shuliak Kit (2017)link

Karyna Shuliak's brother, Jabor Shuliak, also received a kit: "23andme kit for jabor — We have just used your email address to register Jabor's DNA kit" (EFTA02324345). His results were delivered to the 23andMe account: "Your ancestry report: Your DNA Family" sent to "Jabor" (EFTA00453790).

The Palm Beach Kits (December 2016)link

"We have received the four 23 and Me Kits to 71st street... Please advise if you would like them Fed Ex'd to PB for tomorrow delivery?"

— December 27, 2016 (EFTA02199016)

Four kits were FedEx'd to Palm Beach for distribution.

Additional Amazon Orders (March 2017)link

"Your Amazon.com order of 4 x '23andMe DNA Test - Ancestry...'"

— March 14, 2017 (EFTA02207612)

Unnamed Kit Recipientslink

The full-text corpus reveals a systematic pattern. Multiple instances of Lesley Groff sending kits to unidentified recipients on Epstein's behalf: "Jeffrey would like me to send you a DNA kit called '23and Me'. Please let me know what address I should send to!" (EFTA00451098) — at least four separate outreach emails to different people (EFTA00451111, EFTA00451112, EFTA00451113).

The 30-Kit Bulk Order (June 2017)link

The largest order was placed through Sultan Bin Sulayem — the chairman of DP World, the Dubai-based port operator. 23andMe's compliance team flagged the order:

"Our shipment warehouse specially reviews large orders for compliance with the 23andMe Terms of Service. So that I may prioritize the release of your order through this review process, please reply to this message with the intended use of the kits in your recent purchase."

— 23andMe Customer Care, May 23, 2017 (EFTA02214068)

Notably, the email was addressed to "Hello Jeffery" — suggesting the order was placed under Epstein's name or linked to his account — despite Sultan being the listed customer.

Sultan provided a cover story:

"I have purchased one kit 3 months ago and it was interesting to see my results. I put a large purchase of Ancestry test kits on behalf of many co-workers in my company who wanted to do the same test."

— Sultan Bin Sulayem, May 23, 2017 (EFTA02214079)

The order was approved but then failed due to insufficient PayPal funds. Sultan was still trying to resolve it in June:

"I assumed you have not received my package yet I ordered 30 test kits"

— Sultan Bin Sulayem, June 3, 2017

When the kits were eventually reordered, 23andMe rejected the shipment because they were being sent outside the United States, violating their Terms of Service:

"The 23andMe Personal Genome Service... is only available for purchase in the United States and must be used in, and returned for analysis from within, the United States in order for us to comply with applicable laws."

— 23andMe Customer Care (EFTA02217606)

Epstein's calendar tracked the Sultan delivery: "When will Sultan send the DNA kit?" — a July 19, 2017 reminder (EFTA02224464).

The $6,084 Bulk Orderlink

A 23andMe order confirmation billed directly to "Jeffrey Epstein, 9 E 71ST ST, NEW YORK" on AmEx ****4009 totaled $6,084.95 — a mass purchase of multiple kits (EFTA00454054). Additional orders followed in serial: another on June 8, 2017 (EFTA00454120).

Epstein's Own 23andMe Account — Under a Pseudonymlink

The 23andMe account linked to jeeproject@yahoo.com was registered under the name "sam epstein". A referral program email was sent to this alias (EFTA01970861), and more significantly, a notification arrived: "A Relative sent you a message on 23andMe" — to "sam epstein" at jeeproject@yahoo.com (EFTA01188647). Epstein was actively using 23andMe's DNA relative-matching feature under a pseudonym.

Epstein Promoting DNA Testinglink

Epstein didn't just order kits — he actively encouraged people to test their DNA:

"you should sign up for 23 and me, do your dna"

— Jeffrey Epstein, July 11, 2013 (EFTA01758716)

Analyzing the Datalink

The DNA collection wasn't passive. Leon Peshkin — a Harvard researcher — offered to personally analyze Epstein's genetic data:

"If you do not have someone else who can do this for you, I am happy to take your 23&me data and run it through Promethease, then give you a summary of whatever noteworthy results come out."

— Leon Peshkin, May 2018 (EFTA02446063)

Peshkin asked for Epstein's 23andMe account credentials or raw data file. This suggests Epstein had completed his own 23andMe test and that the results were being actively analyzed by Harvard researchers.

Across the archive, Epstein ordered or distributed at least 42+ DNA testing kits between 2013 and 2017 — including 30 for Sultan's bulk order, 4 to Palm Beach, 4 from Amazon, 2 for the Chomskys, kits for Woody Allen, Aziza, Jabor Y., Jabor Shuliak, and multiple unnamed recipients identified in the full-text corpus.

Part VI: The DNA Database — A USVI Tax Shelterlink

Meanwhile, Epstein's personal notes from October 2011 include a cryptic reference:

"re dna database"

— Epstein's personal name list, alongside Reid Hoffman and others, October 27, 2011 (EFTA01854144)

This wasn't idle musing. The full-text DOJ corpus reveals that Epstein formalized the DNA database as a government-certified business in the US Virgin Islands, receiving massive tax benefits.

In January 2012, Epstein prepared a business plan for Financial Infomatics Virgin Islands (FIVI), operating through his entity Southern Trust Company, Inc. at 6100 Red Hook Quarter, Suite B-3, St. Thomas. The plan states:

"FIVI's goal is to build one of the world's largest DNA database and develop a data mining platform for the database to be available through the internet. With over 200 million profiled US internet users and up to 2 billion worldwide users the goal of discovering trends related to diseases and assisting in health preservation has vast possibilities."

— Financial Infomatics Virgin Islands Business Plan, January 2012 (EFTA01173442)

The plan describes FIVI's purpose as "data acquisition and the development of predictive models using a comprehensive database to bridge the fields of data mining and bioinformatics." The target platform would apply "genomics, proteomics, structural biology, disease modeling, and biomedical engineering" through servers located in the US Virgin Islands. Revenue projections: $3 million in Year 1, scaling to $5.6 million by Year 4.

The business plan names Epstein as founder and CEO, describing him as "universally renowned for his complex mathematics skills" and noting his intent to operate within the University of the Virgin Islands Research and Technology Park.

On the basis of this plan, the USVI Economic Development Commission granted Southern Trust Company a formal certificate for a "Category IIA designated service business providing extensive DNA database and to develop a data-mining platform for the database to be available through the Internet" (EFTA01166297). The benefits were extraordinary:

The certificate lists the sole member: Jeffrey Epstein — 100% ownership, at the Red Hook Quarter address.

The DNA database wasn't just a plan on paper. In February 2015, Richard Kahn — Epstein's accountant — requested an invoice from Ben Goertzel, the AI researcher, for $30,000 for "Algorithm DNA database management" to be billed to Southern Trust Company Inc.:

"can you please send an invoice via email for Algorithm DNA database management to: Southern Trust Company Inc., 6100 Red Hood Quarter, B3, St Thomas, USVI 00802"

— Richard Kahn to Ben Goertzel, February 3, 2015 (EFTA01191403)

Goertzel — a PhD in AI who would later become CEO of SingularityNET — was being paid through Epstein's offshore trust to build or manage the algorithms powering a DNA database. The payment was routed through the same entity receiving 90% income tax exemption from the USVI government.

Epstein and the FBI DNA Databaselink

A separate trail reveals Epstein's concern about his own DNA in law enforcement databases. Lawrence Wood, a Florida law enforcement contact, wrote to Epstein: "It is Florida DNA Database... I do not have access to any other DNA Database..." (EFTA02517096). The FBI Laboratory also contacted Epstein's legal team: "the FBI Laboratory-Federal DNA Database Unit was contacted and reported to the DOJ that your DNA sample is not on record" (EFTA02517233).

While building the world's largest private DNA database, Epstein was simultaneously checking whether law enforcement had his DNA on file.

Part VII: The Cloning Conversationlink

In November 2011 — two years before the skin biopsy — Epstein and George Church exchanged emails that reveal the most radical dimension of their relationship.

Epstein wrote:

"sorry, you can;t make it, . did the cloning isssue , give you pause?"

— Jeffrey Epstein, November 18, 2011 (EFTA01850962)

Church replied:

"Yes. I'm working toward this goal fairly rapidly, but trying to do so in a way that minimizes risk to the field. James Wilson (who happened to be my physician, in the 1990s) set back the field of gene therapy by a decade by rushing."

"My lab is good at conceiving of radically new technologies as well as improving throughput and quality by factors of ten. Given a couple of years and decent funding, this would become much more reasonable. I'm too busy dong it well to get distracted by trying to do it badly."

— George Church, November 18, 2011 (EFTA01850962)

Church confirmed he was "working toward this goal fairly rapidly" — the goal being human cloning. His caution wasn't about the science or ethics; it was about PR risk to "the field." He compared the situation to James Wilson's gene therapy trial at Penn, where a patient died in 1999, setting the field back by a decade. Church was asking for "a couple of years and decent funding."

Two days later, Church described his organization PersonalGenomes.org as including "adult human tissue cloning & genome engineering" among its activities (EFTA01851285). Epstein responded: "I fully understand, why don't you come and i won't mention it. i just find it intellectually amusing."

The CRISPR gene drive collaboration was real. In April 2017, Martin Nowak — a Harvard mathematician and Epstein-funded researcher — sent Epstein a new paper on using CRISPR gene drive technology in natural populations with the note: "the collaboration with george church was induced by you!!" (EFTA00707374). Epstein was credited with catalyzing Church's gene drive research program.

Part VIII: Human Germline Editing — The Bryan Bishop Partnershiplink

The most explosive finding in the full-text corpus is a concrete, operational partnership between Epstein and Bryan Bishop — a Texas-based biohacker and gene editing advocate — to develop human germline genetic modification.

In September 2018, Bishop sent Epstein two documents:

"References for tech diligence on embryo editing" "A long-form writeup of our concept"

— Bryan Bishop, September 4, 2018 (EFTA02624289)

The language is unmistakable: "our concept" — a shared plan for human embryo editing, with technical references for investor diligence.

One month later, Bishop reported from Tokyo:

"Last week, Japan announced that they are allowing human embryo gene editing... By tremendous fortune, I happened to be in Tokyo last week speaking with a handful of investors. I got a bite (and now the question is, do I want to take their money....). One of the new references in the attachment ('Generation of human oogonia...') is a recent development regarding in vitro gametogenesis, i.e. producing sperm/egg cells from other tissues. Eventually this will mean we can make practically unlimited modifications to the cells before generating an embryo. This isn't a requirement for our initial work but it's a very important direction that will unlock more commercial opportunities."

— Bryan Bishop, October 16, 2018 (EFTA01019549)

Epstein replied with a focus on legal risk:

"we need to get a read on legal. first. cant do anything where US rules apply to us citizens regardless of where.? its such a great subject. what type of investors."

— Jeffrey Epstein, October 16, 2018 (EFTA01019549)

Epstein wasn't dismissing the idea — he was asking about jurisdictional arbitrage. "Can't do anything where US rules apply to us citizens regardless of where" reveals an explicit strategy: find countries where American laws don't reach to conduct human embryo editing. The same pattern he used for Steven Victor's offshore cellular therapy and his own DNA database tax shelter.

The timing is critical. On November 26, 2018 — six weeks after this exchange — news broke that Chinese scientist He Jiankui had created the world's first CRISPR-edited babies. Epstein's response:

"isnt it nice to hear things before they actually happen"

— Jeffrey Epstein, November 27, 2018 (EFTA02614588)

The recipient replied: "Very cool." The email was cc'd to Eva Dubin — wife of hedge fund manager Glenn Dubin, a close Epstein associate. Epstein appeared to claim advance knowledge of the CRISPR baby announcement — which had shocked the scientific world.

That same week, Epstein forwarded to Steve Bannon a ScienceMag article about a "noted biologist" (George Church) defending gene-editing babies (EFTA02613778). He also forwarded a Nature article: "Where in the world could the first CRISPR baby be born?" (EFTA02618078) — the same month he was discussing overseas embryo editing with Bishop.

Meanwhile, Barnaby Marsh — an Epstein associate — was scouting Church's lab for talent willing to push boundaries. He flagged a Church lab student to Epstein as having "a very good creative mind and is not afraid to break rules... rare" (vol00009-efta01018068-pdf).

Part IX: The $10 Million Portfolio — Church's Biotech Investment Proposallink

In July 2014, George Church sent Epstein a detailed proposal for investing $10 million across a portfolio of biotech ventures from his lab ecosystem:

"Many thanks for your very encouraging words yesterday morning. This is already a super interesting experiment (even with $0 spent), since I am looking at my whole ecosystem of companies and unassigned inventions totally differently."

— George Church, July 11, 2014 (EFTA00631419)

The portfolio:

Three months later, Luhan Yang — Church's postdoc and co-founder of eGenesis — pitched Epstein directly:

"Dear Jeffrey, It was nice talking with you on the phone yesterday. I look forward to discussing with you about the business at eGenesis, in which we deliver human transplantable organ by engineering animals. To follow up our last proposal of convertible note, I attached our proposed term sheet in which we offer 15% discount rate and 8% interest rate for $1.5 million investment as convertible note. Alternatively, if you wish, we propose the company pre-money evaluation of $15 million and offer you 9.09% eGenesis preferred share with your $1.5 million investment."

— Luhan Yang, October 24, 2014 (EFTA02676772)

The conference call preceding this pitch — Epstein, Church, Clement, and Yang — listed Epstein as "LEADER." He wasn't just a passive funder. He was directing the conversation.

Part X: The Supercentenarian Programlink

One component of Church's $10 million investment proposal was Androcyte LLC — a company dedicated to sequencing the genomes of people who had lived past 110 years old.

James Clement, who led the program, explained the business model to Epstein:

"The Androcyte business plan is to patent products based on genomic (and epi-genomic) variants which are unique to one or more supercentenarians (SC). Each such DNA variant can be used to design and manufacture variant-specific RNAi molecules, proteins, and CRISPR guide-RNAs. The CRISPR is used for changing DNA in human cells (stem cells, neurons, etc) to match the SC variant or reversible activation or inhibition of the SC-impacted gene."

— George Church, forwarding Androcyte business plan, September 6, 2014 (EFTA02387794)

In other words: identify the genetic variants that let some people live past 110, then use CRISPR to edit those variants into other people's cells. The approach combined genome sequencing, stem cell engineering, and gene editing into a single commercial pipeline.

Clement detailed the company history:

"When we started in January of 2010, we raised $100,000 from three investors for Acron Cell LLC. As you may recall, I dissolved the original company, Acron Cell LLC, and sold the assets to a new Florida company called Androcyte LLC, in 2011."

Church had 2% advisory equity. Epstein questioned the business model:

"is there and was there a biz plan? how does the co intend to make money?"

The answer was clear: patent the longevity genes, manufacture the CRISPR tools to edit them into human cells, and sell the therapies. The full-text corpus reveals the formal Androcyte LLC Subscription Agreement — offering 10% membership units for $200,000 (EFTA01190585) — and the company's tax filings (Form 1065, 2012) showing its formal financial structure (EFTA00593235).

A conference call on October 21, 2014 brought together Epstein, Church, Clement, and Luhan Yang for what the calendar listed as a "2:00pm Conf call w/George Church, James Clement and Luhan Yang (JE is LEADER)" (EFTA02092253). Clement signed his emails as "J.D., LL.M., Supercentenarian Research Study."

Part XI: Nectome — Preserving the Brainlink

In March 2018, Epstein shared a link to Nectome — a brain preservation startup — with Joscha Bach:

"do you know them please not"

— Jeffrey Epstein, March 15, 2018 (EFTA02508072)

That same day, Masha Drokova — a venture investor — independently flagged Nectome to Epstein: "super risky but very fun company I'd love to invest but afraid of" (EFTA02508066). Epstein's network was converging on brain preservation from multiple directions.

Bach replied:

"Except for Ed Boyden not personally. Sam Altman has signed up as far as I know. As always, chances that the current plan for restoring memory from connectome works one day are quite close to nothing but not absolute zero. Structure might be better preserved than in traditional cryo, but tissue gone."

Sam Altman — now CEO of OpenAI — had reportedly paid $10,000 to be on Nectome's waiting list for brain preservation.

One month later, Bach reported back after meeting Nectome's CEO in person:

"While in SF, I have met Robert McIntyre (the CEO of Nectome) and spent an evening with him. I got the impression that he is sincere and smart, but Nectome is just a two people show at this point, with a 2M runway. Robert hopes to be able to extract information about mental states from his preserved nervous tissue in a few years from now. I don't believe that they have a meaningful shot at reviving people, but then, nobody really does."

— Joscha Bach, April 15, 2018 (EFTA02470197)

An associate from Epstein's circle made the connection between brain preservation and Epstein's personality explicit:

"your connections are limitless!!! ... I told him you were the hardest brain to cryopreserve because going so fast always it must overheat!!"

— Gianni Serazzi, November 29, 2018 (EFTA02613159)

Even Jean Luc Brunel — a key Epstein trafficking associate — participated in this thread, recommending that Epstein read "Connectome by Sebastian Seung" in June 2012 (EFTA00936680).

Nectome represented the most radical endpoint of Epstein's preservation obsession: not just storing DNA or cells, but attempting to preserve the mind itself.

Part XII: Young Blood and the Vampire Memolink

Epstein's interest in genetic preservation was intimately connected to his obsession with aging reversal. Boris Nikolic forwarded him research on parabiosis — the experimental practice of transfusing young blood into older subjects:

"LOVE how it starts 'Memo to mature, health-minded vampires: You might want to consider limiting your treats to victims under age 30.' Jee was right all along!!!!!!!!!!!!"

— Jeffrey Epstein (EFTA02031516)

The "Jee" appears to be a self-reference — Epstein declaring that he "was right all along" about the value of young blood. Given his documented predation on minors, the joking reference to "victims under age 30" takes on a darker resonance.

Barry Josephson reinforced the theme:

"All you need is a blood transfusion from the pack and you reverse aging!!"

— Barry Josephson to Epstein (EFTA01801501)

When Richard Joslin shared a Guardian article — "Infusions of young blood may reverse some effects of ageing" — Epstein's response was characteristically dismissive: "i don;t know any one who is old" (EFTA01928350).

The Allen Institute Report — From Bill Gates's Circlelink

In September 2017, someone in Epstein's network forwarded a detailed trip report from the Allen Institute Bioscience & Philanthropy Summit — originally authored for Bill Gates. The report covered Tony Wyss-Coray's parabiosis research in detail:

"parabiosis or the effect of sharing components of 'young' blood with aged tissues appears to return levels of youthfulness in function... Across a large population cohort ranging in age from 20-106 years, about a dozen proteins have been identified that change in character and are being proposed to act as biomarkers for the aging process."

— Allen Institute Trip Report, forwarded to Epstein, September 25, 2017 (EFTA00640752)

The same report covered false memory implantation in mice, immune cells that rewire the brain, "cracking the morphogenetic code" for cell regeneration, and Ted Berger's hippocampal prosthetics — technologies for memory implants. Epstein was receiving cutting-edge bioscience intelligence from Gates's inner circle.

In October 2017, an associate sent Epstein a curated list titled "Scientists and Science of Interest," which included:

"1. Tony Wyss-Coray (Stanford) - Youth, aging, parabiosis, biomarkers... 7. Ted Berger (USC) - Memory implants... 8. Irv Weissman (Stanford) - stem cells"

— October 3, 2017 (EFTA02361620)

By 2018, articles on young blood transfusion clinics opening in New York were circulating in Epstein's email — including a Peter Thiel profile noting his "very, very interested in young people's blood" (EFTA02455360).

Part XIII: The Illumina Connection — From Genome Sequencing to $9 Million Stock Betlink

The thread connecting Epstein to Illumina — the world's dominant DNA sequencing company — runs deeper than the $11,400 genome sequencing payment. It reveals a financial relationship mediated by Boris Nikolic, Epstein's key contact in the biotech investment world.

In February 2014, Nikolic shared inside intelligence with Epstein:

"We are in the process of entering into an agreement with Illumina, the leading DNA sequencing company globally that would provide us unique access to sequencing application start-ups that join their incubator program... This is a great news as this will feed a lot of our pipeline. Illumina is now a world leader in sequencing — so anything that has to do with sequencing there is no better partner."

— Boris Nikolic, February 12, 2014 (EFTA01933592)

Two years later, in January 2016, Nikolic reported the launch of Grail — an Illumina spinoff for early-stage cancer detection via DNA blood tests, backed by Bill Gates and Jeff Bezos:

"Just announced 30min ago and a press is just starting... It is an amazing deal. I warehoused it into my fund with the rest of deals — over 20MM already spent and 40MM committed — before launching a fund — crazy ;) I did not want my name — Bill is so much better looking ;)"

— Boris Nikolic, January 10, 2016 (EFTA02361231)

Epstein's reply: "Good work" (EFTA02475408).

Nikolic had warehoused Grail — a company that would later be valued at billions — into his fund, and was reporting to Epstein in real-time, 30 minutes after the public announcement. He had already spent $20 million and committed $40 million in genomics deals.

Then, on March 11, 2019 — four months before his arrest — Epstein sent a one-line email to Richard Kahn:

"buy 30k shares of illumina"

— Jeffrey Epstein, March 11, 2019 (EFTA02630384)

At Illumina's trading price of approximately $300 per share in March 2019, this order represents roughly $9 million in stock. This wasn't a passive scientific interest — it was one of the largest single stock purchases documented in Epstein's email archive, a massive financial bet on the company that sequenced his own genome.

Epstein also received a personalized invitation from Human Longevity Inc. — the genomics company founded by Craig Venter — welcoming him to "the future of human health" through their Health Nucleus program (EFTA02358393).

Part XIV: Steven Victor and IntelliCell BioScienceslink

Dr. Steven Victor — a New York dermatologist — repeatedly pitched Epstein on stem cell investments:

"Can you please invest in my Stem Cell Biotech Company as a convertible note (loan) for $250-500k"

— Steven Victor to Epstein, February 8, 2017 (EFTA02342405)

Epstein forwarded the request with: "can you believe?" Harry Fisch replied: "terrible terrible terrible."

But Victor had been sending Epstein stem cell materials for years — earlier than previously documented. In March 2010, Victor emailed Epstein "pictures fibroblast isologen" with a MedStem/Isologen presentation attached (EFTA00762028) — pitching fibroblast-based cosmetic treatments three years before the PGP skin biopsy. This establishes that Epstein's interest in fibroblast preservation predated his relationship with Church's lab.

Additional documented contacts:

• January 2011: Victor sends Epstein the IntelliCell BioSciences Private Placement Memorandum (PPM) (EFTA02395451)
• November 2012: Victor forwarded IntelliCell's FDA Establishment Registration Certificate for "Human Cells, Tissues, and Cellular Based Products" (vol00009-efta00633529-pdf)
• October 2013: Victor forwarded IntelliCell press release on stem cells for Bell's Palsy and Type I Diabetes (EFTA01951603)
• March 2014: Victor forwarded IntelliCell press release on stem cells and Dr. Andrews (EFTA01931157)
• July 2015: Victor told Epstein: "You need stem cells asap!!! LOL" (EFTA02347086)

IntelliCell BioSciences was a publicly traded stem cell company (ticker: SVFC) that processed fat tissue to extract stem cells for therapeutic use. The company produced peer-reviewed research acknowledging "IntelliCell BioSciences and Dr. Steven Victor, MD for implementation of the SVF isolation protocol using ultrasonic cavitation" (EFTA01193376).

Karyna Shuliak as Patientlink

The Regen Medical records reveal that Karyna Shuliak — Epstein's girlfriend who coordinated his California Cryobank paperwork — was herself a patient at Victor's stem cell practice. A "Copy Release of medical records for Karyna Shuliak" was processed by Regen Medical on July 12, 2012 (EFTA01112027).

Offshore Cellular Therapylink

In August 2013, Victor asked Epstein a revealing question:

"I need an off shore home for my cellular therapy. Need friendly government."

— Steven Victor, August 2013 (vol00009-efta00706648-pdf)

Epstein responded with specific jurisdictional advice:

"st thomas is United States jurisdiction. THE british virgins or cuba, or the st kitts, dominica or worth a shot."

Victor was looking for regulatory havens to practice cellular therapy outside US jurisdiction — and Epstein, who owned properties in the US Virgin Islands, was his advisor on where to set up. Victor shared links to stem cell clinics in the Cayman Islands, Costa Rica, and Bahamas.

The Nygard Connectionlink

In March 2011, Victor asked Epstein: "do u know Peter Nygard?" Epstein responded: "no." (EFTA01836904)

Peter Nygard — the Canadian fashion mogul — was later arrested in December 2020 on sex trafficking charges strikingly similar to Epstein's. Nygard was also obsessed with stem cell treatments and anti-aging technology, reportedly funding stem cell research in the Bahamas. Victor's inquiry connecting these two men through stem cell interests is documented but unexplored.

Part XV: IVF, Frozen Embryos, and Fertility in Epstein's Circlelink

Fertility technology was not just a scientific interest — it was embedded in the personal lives of Epstein's associates, and he involved himself directly.

Rich Kahn — an Epstein employee — wrote in June 2009:

"I am so grateful for your support when we went through IVF which allowed us to have such a wonderful son. We still have 3 frozen embryos and I would like to put them to use however my wife wants to wait 6 more months."

— Rich Kahn, June 10, 2009 (EFTA02443624)

Epstein forwarded the message with: "i couldn't make this up."

Ghislaine Maxwell's IVF Paymentlink

The kabasshouse financial database contains a striking transaction on Ghislaine Maxwell's credit card:

October 17, 2013: $1,000 payment to "Nyu School of Med Ivf" (212-263-0041, NY) — Card 0629, cardholder: GHISLAINE MAXWELL

— Financial transaction, EFTA01576941

A $1,000 payment to NYU's In Vitro Fertilization clinic, charged to Maxwell's card. The purpose of this payment — consultation, treatment, or something else — is not explained in the archive.

Lesley Groff's IVFlink

Epstein's executive assistant Lesley Groff — who coordinated nearly every logistical aspect of his DNA program — was herself undergoing IVF. In November 2006, she wrote to Epstein: "I have 4 eggs that are fertilizing normally. Tomorrow is the implant" (fb689e475f271b9c80399d6cc0fc0c8b). Epstein was directly informed about his assistant's reproductive process.

Fertility Clinic Connectionslink

Epstein's network included direct connections to New York's fertility establishment. In February 2016, someone in his circle sought his opinion on fertility doctors:

"I would love your opinion on whether you think it would be better to go to the doctor Romoff recommended or the doctor who was recommended to her by Eva."

— February 2016 (EFTA02473498)

The two options were New York Fertility Services (nyfertility.org) and Dr. Zev Rosenwaks at the Center for Reproductive Medicine (ivf.org) — Cornell's renowned fertility program. Epstein was being consulted as a trusted advisor on fertility clinic selection.

Mark Fisher — an associate going through cancer treatment — used Epstein's financial support for sperm banking:

"Making my first expenditure from your generosity. Going to the sperm bank to make a deposit before starting chemo. The interest rate is 0 and they charge you for the visit and long term banking fees. So weird you can not make this stuff up."

— Mark Fisher, December 18, 2009 (vol00009-efta00766608-pdf)

Part XVI: The Financial Infrastructurelink

The combined email archive and kabasshouse financial database reveal a far more extensive financial footprint than previously documented:

Total documented and proposed expenditure on genetic/biological infrastructure: approximately $16 million, including the Illumina stock purchase, USVI DNA database investment, and Church portfolio proposals.

The $449,960 in payments from Regen Medical PC — Steven Victor's company at an Upper East Side address (10021) — combined with the $100,000 to Victor Dermatology (2006) and $25,000 to Victor Products (2008), brings total documented payments to Victor's companies to approximately $575,000.

Part XVII: The Networklink

The archive reveals a specific network of people involved in Epstein's biological material infrastructure:

The Scientistslink

• George Church — Harvard geneticist, Personal Genome Project founder, CRISPR co-developer. Arranged Epstein's skin biopsy, managed his cell lines, proposed $10M investment across biotech ventures, discussed cloning "working toward this goal fairly rapidly"
• Joe Thakuria — MGH Medical Director of PGP. Performed skin biopsy, saliva collection, dual exome sequencing. Work was largely pro bono
• James Clement — Supercentenarian researcher, Androcyte LLC founder. Collected genomes of 110+ year olds
• Leon Peshkin — Harvard researcher whose single-cell embryo profiling was Science's Breakthrough of 2018. Reported directly to Epstein (EFTA02605378), offered to analyze his 23andMe data
• Steven Victor — Dermatologist, IntelliCell BioSciences shareholder. Pitched fibroblast treatments (2010), stem cell investments, offshore cellular therapy
• Luhan Yang — George Church's postdoc, co-founder of eGenesis. Pitched Epstein directly on $1.5M xenotransplantation investment
• Bryan Bishop — Biohacker and gene editing advocate. Co-developed "human germline genetic modification outline" with Epstein, explored overseas embryo editing jurisdictions
• Ben Goertzel — AI researcher (later CEO of SingularityNET). Paid $30K through Southern Trust for "Algorithm DNA database management"

The Investment Brokerslink

• Boris Nikolic — Former Gates Foundation science advisor. Connected Epstein to Illumina pipeline, reported Grail launch in real-time, warehoused $40M+ in genomics deals
• Barnaby Marsh — Scouted Church lab talent for Epstein, flagging students who were "not afraid to break rules"
• Martin Nowak — Harvard mathematician, Epstein-funded. Credited Epstein with inducing Church CRISPR gene drive collaboration

The Medical Providerslink

• Harry Fisch — NYC urologist who referred Epstein to California Cryobank
• California Cryobank / Kaitlyn Fraterman — Semen storage program, New York office. Signed agreement since May 2014
• Massachusetts General Hospital — Skin biopsy, fibroblast culture, genome sequencing
• 23andMe — DNA testing kits distributed across Epstein's network
• Human Longevity Inc. — Craig Venter's genomics company, enrolled Epstein in Health Nucleus program

The Associates Who Received DNA Kitslink

• Woody Allen — 23andMe kits delivered to his home via Epstein's staff (September 2016)
• Noam and Valeria Chomsky — 2 kits sent via Amazon (April 2017)
• Sultan Bin Sulayem — 30 kits ordered (June 2017), rejected by 23andMe for overseas use
• Jabor Y. — Qatari contact, kit offered February 2017
• Jabor Shuliak — Karyna's brother, kit registered and results received
• "Aziza" — Kit delivered via Amazon (May 2017)
• 4+ unnamed recipients — Individual outreach emails from Groff
• 4 unnamed recipients — Kits FedEx'd to Palm Beach (December 2016)
• 4 unnamed recipients — Ordered from Amazon (March 2017)

The Intermediarieslink

• Lesley Groff — Executive assistant who coordinated all logistics: biopsy appointments, genome sequencing follow-ups, 23andMe orders, Cryobank paperwork
• Karyna Shuliak — Girlfriend who coordinated Cryobank forms, ordered DNA kits, and was herself a patient at Victor's Regen Medical practice
• Rich Kahn — Employee who processed payments, requested Goertzel DNA database invoice, and received IVF support from Epstein

Part XVIII: What "Project Venus" Might Belink

The documentary evidence reveals something that functions exactly as the "Project Venus" label describes:

A systematic program to collect, preserve, catalogue, and commercially exploit genetic material across multiple facilities, jurisdictions, and individuals, managed by a network of Harvard scientists, MGH physicians, fertility specialists, biohackers, AI researchers, and personal assistants — with a formal USVI tax-shelter business structure and active plans for human germline editing.

The components:

1. Epstein's own biological material: Fibroblast cell lines (Harvard/MGH, liquid nitrogen), iPS cells (in creation), full genome sequence (Illumina), dual exome sequencing (saliva + fibroblast — first person to have two sources sequenced), sperm (California Cryobank, 2012–2018+)

2. DNA from his network: 42+ 23andMe kits distributed to associates including Woody Allen, Noam Chomsky, Sultan Bin Sulayem, Jabor Y. (Qatar), Jabor Shuliak, and unnamed recipients across New York, Palm Beach, and attempted overseas destinations. Epstein maintained his own 23andMe account under the pseudonym "sam epstein" with DNA relative-matching active

3. The USVI DNA database: A government-certified business (Southern Trust / FIVI) with 90% income tax exemption, described as aiming to build "one of the world's largest DNA databases" with a bioinformatics data-mining platform, managed by AI researcher Ben Goertzel at $30,000 via Epstein's offshore trust

4. Supercentenarian genomes: Androcyte LLC's collection of genetic variants from people who lived past 110, intended for CRISPR-based longevity therapies. $200K investment proposed

5. Human germline editing: Active partnership with Bryan Bishop developing a "human germline genetic modification outline," exploring overseas jurisdictions to circumvent US law. Epstein appeared to claim advance knowledge of the Chinese CRISPR baby announcement

6. The PGP biobank: Church's Harvard database of genomes and stem cells, described as the only collection "properly consented for broad commercial use." Church confirmed working toward human cloning "fairly rapidly"

7. Brain preservation research: Nectome evaluation, cryopreservation jokes, consciousness conference attendance

8. The Illumina pipeline: Boris Nikolic's insider access to Illumina's incubator, real-time reporting of the Grail spinoff to Epstein, and Epstein's $9 million stock purchase four months before arrest

9. Xenotransplantation: $1.5M investment pitch from eGenesis for CRISPR-engineered pig organs, with Epstein designated as conference call "LEADER"

Whether any of this was formally called "Project Venus" remains unconfirmed. But the infrastructure was real, documented, operational, and far more extensive than previously understood.

Part XIX: Timelinelink

Part XX: What the Documents Showlink

The Epstein email archive and full-text DOJ corpus document a thirteen-year program of systematic biological material collection, genetic data gathering, and reproductive technology development — from 2006 to 2019 — building on scientific relationships that began with the Personal Genome Project and expanding into human germline editing, offshore DNA databases, and multimillion-dollar genomics investments.

What is documented:

1. Epstein's own cell lines were grown and stored at Massachusetts General Hospital. Fibroblast cultures in liquid nitrogen, slated for iPS cell creation. His full genome was sequenced through Illumina. He was the first person to have dual exomes (saliva + fibroblast) sequenced through the PGP. His sperm was stored at California Cryobank for at least six years (2012–2018+), with a signed specimen storage agreement from May 2014.

2. 42+ DNA testing kits were distributed to associates including Woody Allen, Noam Chomsky, Sultan Bin Sulayem, Jabor Y. (Qatar), Jabor Shuliak, and unnamed recipients across New York, Palm Beach, and attempted overseas destinations. Epstein maintained his own 23andMe account under the pseudonym "sam epstein" with DNA relative-matching enabled. A 30-kit bulk order was rejected by 23andMe for violating their US-only Terms of Service.

3. A formal DNA database business was established in the US Virgin Islands through Southern Trust Company / Financial Infomatics Virgin Islands, receiving a 10-year USVI Economic Development Commission certificate with 90% income tax exemption and 100% gross receipts tax exemption. AI researcher Ben Goertzel was paid $30,000 for "Algorithm DNA database management" through this entity. The business plan stated the goal of building "one of the world's largest DNA databases."

4. Human germline editing was actively planned. Bryan Bishop and Epstein developed a "human germline genetic modification outline" and explored overseas jurisdictions (Japan, others) to circumvent US regulations. Epstein appeared to claim advance knowledge of the Chinese CRISPR baby announcement. Barnaby Marsh scouted Church lab researchers who were "not afraid to break rules."

5. George Church confirmed working toward human cloning "fairly rapidly" in a 2011 email exchange with Epstein. Church's caution was about PR risk, not ethics or feasibility. Martin Nowak credited Epstein with inducing Church's CRISPR gene drive collaboration.

6. The Personal Genome Project biobank — where Epstein's cells were stored — was described by George Church as the only stem cell collection "properly consented for broad commercial use." This wasn't just academic research. It was positioned as a commercial asset.

7. Church proposed a $10 million biotech investment portfolio spanning supercentenarian genome patenting (Androcyte), xenotransplantation via CRISPR pig organs (eGenesis — $1.5M at $15M pre-money valuation), gene drives, aging reversal, and de-extinction. Epstein was designated "LEADER" of the investment conference calls.

8. Brain preservation was actively evaluated. Epstein discussed Nectome, whose waiting list included Sam Altman. Associates joked about preserving Epstein's brain through cryogenics. Jean Luc Brunel recommended reading about the connectome.

9. The Illumina connection ran through Boris Nikolic's insider access to the company's incubator program, Nikolic's real-time reporting of the Grail spinoff (with $40M committed before even launching a fund), and Epstein's $9 million Illumina stock purchase four months before his arrest.

10. The financial infrastructure included at least $575K to Steven Victor's companies (Regen Medical, Victor Dermatology), $400K+ required investment in the USVI DNA database, $13K+ in genome sequencing payments, annual sperm storage fees, thousands in DNA kit purchases, and a ~$9M bet on Illumina stock — totaling approximately $16 million in documented and proposed expenditure on genetic/biological infrastructure.

11. The stated motivation — revealed in Epstein's own words — was whether "beauty resides in the DNA." This question, from the man who would go on to fund designer baby research, plan offshore embryo editing, and operate a DNA database tax shelter, frames the entire enterprise: genetic material as a resource to be collected, analyzed, commercially exploited, and deployed across jurisdictional boundaries.

What is not documented: The term "Project Venus" does not appear in the archive or the 1.3M-document DOJ corpus. No evidence of "200 anonymous genomes" was found. No Boston Children's Hospital connection was confirmed in the emails. These claims from external sources may reference documents outside the email archive, or may be based on reporting that draws from different Epstein document sets.

The email archive does not explain what ultimately happened to Epstein's cell lines at Harvard, whether his genome data was shared with third parties, whether the USVI DNA database was ever populated with the collected 23andMe data, whether the Bryan Bishop germline editing project progressed beyond the planning stage, or who controls his biological material now. These are open questions that no existing document answers.

Report generated from primary source analysis of the Epstein email archive and 1.3M-document full-text DOJ corpus. All EFTA references link to original documents. No editorial interpretation has been added beyond what the emails and government documents themselves state.